Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
422 Leser
Artikel bewerten:
(2)

Fishawack Health Enhances Its Omnichannel Offering With The Acquisition Of Analytics-Driven Digital Marketing Agency, closerlook

Finanznachrichten News

As part of its bold growth plans, Fishawack Health announces the acquisition of closerlook, a data analytics and digital native healthcare agency specializing in intelligent omnichannel marketing solutions.

KNUTSFORD, England, June 8, 2021 /PRNewswire/ -- Fishawack Health, a leading global commercialization partner for the life sciences industry, announces the acquisition of Chicago-based closerlook LLC. closerlook is a digital-native healthcare agency that leverages artificial intelligence (AI) and data analytics to develop omnichannel strategies, creative and digital media solutions for life science brands across the entire pre-commercial and commercial lifecycle of a drug.

From left to right: David Ormesher, CEO; Jon Sawyer, President and Chief Operating Officer; Allison Davis, Chief Client Officer; Ryan Mason, Chief Strategy Officer; Dave Reidy, Chief Creative Officer and Steve Tulk, Chief Technology Officer

The award-winning firm's skills and software products in data science, AI, and advanced analytics provide life science brands with real-time insights, providing the ability to develop hyper-targeted and precisely personalized campaigns at scale. This expertise, combined with Fishawack Health's broad spectrum of medical communications, commercial and consulting capabilities, will provide healthcare marketers with unrivaled access to an integrated platform that is designed for competitive advantage.

closerlook's approach to data-driven healthcare marketing is powered by its four interlocking capabilities: omnichannel strategy, conceptual creative and content, digital tactics and media management, and advanced analytics. These are all informed by Backstage Intelligence, the firm's proprietary data and intelligence market hub. The platform uses AI and data science to inform and precisely tailor healthcare professional and patient experiences. Such personalization ensures biopharma companies engage with customers and patients in novel and intelligent ways, driving innovation, and connecting healthcare professionals and patients with the knowledge they need to improve health outcomes and live better lives.

Oliver Dennis, Fishawack Health co-founder, and CEO said: "Traditionally, the healthcare sector has fallen behind when it comes to leveraging the power of innovative technologies to enhance commercial and medical communications strategies. The COVID-19 pandemic has highlighted the necessity of digital communication and the opportunities an omnichannel approach brings. Life science brands need a new breed of partner that offers bespoke teams who bring with them digital and analytics prowess, a rigorous understanding of the science, and the ability to develop impactful strategies and creative solutions.

"Importantly, closerlook's advanced AI and analytics offering can track and optimize performance, delivering increased business results for clients. Through this combination of expertise, we can develop highly intelligent solutions that are integral for developing, launching, and growing brands and portfolios in a complex and crowded marketplace."

David Ormesher, CEO of closerlook, said: "We are energized by the prospect of joining a global team with the breadth and depth of Fishawack Health. I believe that the combination of our AI/advanced analytics-enabled omnichannel strategy, creative, and digital media with Fishawack Health's global consulting, commercial and medical communications capabilities will create a unique commercialization offering for life science brands and healthcare companies looking for growth.

"We have spent over six months getting to know the Fishawack Health leadership, and we are excited about the alignment of vision, purpose, and culture between our two organizations. Over the past year, closerlook has experienced the fastest growth in its history and we expect Fishawack Health to supercharge that even more. We are looking forward to working together to achieve our mission of better health outcomes for patients and greater business results for the biopharma brands that serve them".

About Fishawack Health
Visit www.fishawack.com?and follow us on?Twitter?and?LinkedIn.

Contact:
Natasha Cowan - +44-20-3328-1840
Corporate Communications Manager
natasha.cowan@fishawack.com

Louise Stone - +44-20-3328-1840
Corporate Communications Manager
Louise.stone@fishawack.com

About closerlook
Visit closerlook.com.

Contact:
Liz Mitchell - +1-847-445-6383
Director of Marketing
emitchell@closerlook.com

Advisers involved in this transaction included:
KPMG (Manchester and Chicago) acted on behalf of Fishawack Health for financial and tax due diligence; Sheppard Mullin (San Diego), and Allen & Overy (London) provided legal support; and EY provided tax structuring advice.Houlihan Lokey acted on behalf of closerlook for M&A advice. Gould & Ratner provided legal counsel and KPMG (Chicago) provided tax advice and accounting support.

Photo - https://mma.prnewswire.com/media/1526715/closerlook_Exec_Team.jpg

Logo - https://mma.prnewswire.com/media/1526716/Fishawack_Health_Logo.jpg

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.